189 related articles for article (PubMed ID: 16009400)
1. TAFI and PAI-1 levels in human sepsis.
Zeerleder S; Schroeder V; Hack CE; Kohler HP; Wuillemin WA
Thromb Res; 2006; 118(2):205-12. PubMed ID: 16009400
[TBL] [Abstract][Full Text] [Related]
2. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation.
Chen CC; Lee KD; Gau JP; Yu YB; You JY; Lee SC; Hsu HC; Chau WK; Ho CH
Ann Hematol; 2005 Oct; 84(10):675-80. PubMed ID: 16007424
[TBL] [Abstract][Full Text] [Related]
3. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.
Raaphorst J; Johan Groeneveld AB; Bossink AW; Erik Hack C
Thromb Haemost; 2001 Aug; 86(2):543-9. PubMed ID: 11522001
[TBL] [Abstract][Full Text] [Related]
4. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
[TBL] [Abstract][Full Text] [Related]
5. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
6. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D
Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
[TBL] [Abstract][Full Text] [Related]
7. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
8. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
9. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
10. Factor XIII in severe sepsis and septic shock.
Zeerleder S; Schroeder V; Lämmle B; Wuillemin WA; Hack CE; Kohler HP
Thromb Res; 2007; 119(3):311-8. PubMed ID: 16574200
[TBL] [Abstract][Full Text] [Related]
11. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients.
Voves C; Wuillemin WA; Zeerleder S
Blood Coagul Fibrinolysis; 2006 Sep; 17(6):445-51. PubMed ID: 16905947
[TBL] [Abstract][Full Text] [Related]
12. Tight glycemic control may favor fibrinolysis in patients with sepsis.
Savioli M; Cugno M; Polli F; Taccone P; Bellani G; Spanu P; Pesenti A; Iapichino G; Gattinoni L
Crit Care Med; 2009 Feb; 37(2):424-31. PubMed ID: 19114908
[TBL] [Abstract][Full Text] [Related]
13. [Study of fibrinolysis inhibitors in 117 acute leukemia patients].
Wang W; Ji CY; Ye JJ; Zhu YY; Guo DM; Ji M
Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):183-6. PubMed ID: 18788619
[TBL] [Abstract][Full Text] [Related]
14. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
Hayakawa M; Sawamura A; Gando S; Jesmin S; Naito S; Ieko M
Thromb Res; 2012 Dec; 130(6):906-13. PubMed ID: 22353215
[TBL] [Abstract][Full Text] [Related]
15. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis.
Mesters RM; Flörke N; Ostermann H; Kienast J
Thromb Haemost; 1996 Jun; 75(6):902-7. PubMed ID: 8822584
[TBL] [Abstract][Full Text] [Related]
16. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
Ozeren M; Karahan SC; Ozgur M; Eminagaoglu S; Unsal M; Baytan S; Bozkaya H
Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
[TBL] [Abstract][Full Text] [Related]
18. The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure.
Green J; Doughty L; Kaplan SS; Sasser H; Carcillo JA
Thromb Haemost; 2002 Feb; 87(2):218-23. PubMed ID: 11858480
[TBL] [Abstract][Full Text] [Related]
19. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
20. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
